Beximco Pharmaceuticals (BXP) Competitors

Beximco Pharmaceuticals (LON:BXP) and London Stock Exchange Group plc (LSE.L) (LON:LSE) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.

Which has higher earnings & valuation, BXP or LSE?

Beximco Pharmaceuticals has higher revenue and earnings than London Stock Exchange Group plc (LSE.L). London Stock Exchange Group plc (LSE.L) is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beximco Pharmaceuticals	£7.08T	0.00	£970.84B	£9.32	4.01
London Stock Exchange Group plc (LSE.L)	£2.41B	0.00	N/A	£112.40	N/A

Do insiders & institutionals hold more shares of BXP or LSE?

1.7% of Beximco Pharmaceuticals shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer BXP or LSE?

London Stock Exchange Group plc (LSE.L) received 662 more outperform votes than Beximco Pharmaceuticals when rated by MarketBeat users. Likewise, 71.83% of users gave London Stock Exchange Group plc (LSE.L) an outperform vote while only 64.67% of users gave Beximco Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Beximco Pharmaceuticals	Outperform Votes 108 64.67%	Underperform Votes 59 35.33%
London Stock Exchange Group plc (LSE.L)	Outperform Votes 770 71.83%	Underperform Votes 302 28.17%

Is BXP or LSE more profitable?

Beximco Pharmaceuticals has a net margin of 13.71% compared to London Stock Exchange Group plc (LSE.L)'s net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 13.12% beat London Stock Exchange Group plc (LSE.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beximco Pharmaceuticals	13.71%	13.12%	6.97%
London Stock Exchange Group plc (LSE.L)	N/A	N/A	N/A

Does the media prefer BXP or LSE?

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than London Stock Exchange Group plc (LSE.L). MarketBeat recorded 2 mentions for Beximco Pharmaceuticals and 1 mentions for London Stock Exchange Group plc (LSE.L). Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled London Stock Exchange Group plc (LSE.L)'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beximco Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
London Stock Exchange Group plc (LSE.L)	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is BXP or LSE a better dividend stock?

Beximco Pharmaceuticals pays an annual dividend of GBX 3 per share and has a dividend yield of 8.0%. London Stock Exchange Group plc (LSE.L) pays an annual dividend of GBX 73 per share. Beximco Pharmaceuticals pays out 32.2% of its earnings in the form of a dividend. London Stock Exchange Group plc (LSE.L) pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Beximco Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Beximco Pharmaceuticals beats London Stock Exchange Group plc (LSE.L) on 8 of the 12 factors compared between the two stocks.